Sign in
8-K

Current Report

Werewolf Therapeutics, Inc. Filed Acc 0001193125-26-051455

Exit or restructuring costs · Executive or director change · Regulation FD disclosure

  • Item 2.05 Costs associated with exit or disposal activities
  • Item 5.02 Departure or appointment of directors or officers
  • Item 7.01 Regulation FD disclosure

From the SEC's structured data for this filing

Loading d110809d8k.htm…